Signaling pathways associated with inflammatory bowel disease

Recent Patents on Inflammation and Allergy Drug Discovery

Volumn 4, Issue 2, 2010, Pages 105-117

  Wei, Jia ^a   Feng, Jiexiong ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Crohn's disease; IBD; NF kB; NOD; P38 MAPK; PI3K Akt; Signaling pathway; TLR; Ulcerative colitis

Indexed keywords

CASPASE RECRUITMENT DOMAIN PROTEIN 15; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FAS ANTIGEN; FAS LIGAND; GENE PRODUCT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 23 RECEPTOR; JANUS KINASE; JANUS KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; ORGANIC CATION TRANSPORTER; ORGANIC CATION TRANSPORTER 1; ORGANIC CATION TRANSPORTER 2; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN ATG16L1; STRESS ACTIVATED PROTEIN KINASE; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CROHN DISEASE; ENTERITIS; GENE MUTATION; GENETIC VARIABILITY; HOMEOSTASIS; HUMAN; IMMUNOPATHOGENESIS; IMMUNOPATHOLOGY; INFLAMMATION; MUTATIONAL ANALYSIS; NATURAL KILLER CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ULCERATIVE COLITIS;

ANIMALS; COLITIS, ULCERATIVE; CROHN DISEASE; HUMANS; INFLAMMATION; INTESTINES; NF-KAPPA B; PATENTS AS TOPIC; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TOLL-LIKE RECEPTORS;

EID: 77954050569     PISSN: 1872213X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221310791163071     Document Type: Article

References (158)

1. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347(6): 417-29.
2. Strober W, Fuss IJ, Blumberg RS. The immunology of mucosal models of inflammation. Annu Rev Immunol 2002; 20: 495-49.
3. Danese S, Fiocchi C. Etiopathogenesis of inflammatory bowel diseases. World J Gastroenterol 2006; 12(30): 4807-12.
4. Mizoguchi A, Mizoguchi E. Inflammatory bowel disease, past, present and future: Lessons from animal models. J Gastroenterol 2008; 43(1): 1-17.
5. Noomen CG, Hommes DW, Fidder HH. Update on genetics in inflammatory disease. Best Pract Res Clin Gastroenterol 2009; 23(2): 233-43.
6. Antalis TM, Shea-Donohue T, Vogel SN, Vogel SN, Sears C, Fasano A. Mechanisms of disease: Protease functions in intestinal mucosal pathobiology. Nat Clin Pract Gastroenterol Hepatol 2007; 4(7): 393-402.
7. Bamias G, Cominelli F. Immunopathogenesis of inflammatory bowel disease: Current concepts. Curr Opin Gastroenterol 2007; 23(4): 365-9.
8. Spehlmann ME, Eckmann L. Nuclear factor-kB in intestinal protection and destruction. Curr Opin Gastroenterol 2009; 25(2): 92-9.
9. Schindler JF, Monahan JB, Smith WG. p38 pathway kinases as anti-inflammatory drug targets. J Dent Res 2007; 86(9): 800-11.
10. Mueller T, Podolsky DK. Nucleotide-binding-oligomerization domain proteins and toll-like receptors: Sensors of the inflammatory bowel diseases' microbial environment. Curr Opin Gastroenterol 2005; 21(4): 419-25.
11. Barmada MM, Brant SR, Nicolae DL, Achkar JP, Panhuysen CI, Bayless TM, et al. A genome scan in 260 inflammatory bowel disease-affected relative pairs. Inflamm Bowel Dis 2004; 10: 513-20.
12. van Heel DA, Fisher SA, Kirby A, Daly MJ, Rioux JD, Lewis CM, et al. Inflammatory bowel disease susceptibility loci defined by genome scan meta-analysis of 1952 affected relative pairs. Hum Mol Genet 2004; 13: 763-70.
13. Brant SR, Shugart YY. Inflammatory bowel disease gene hunting by linkage analysis: Rationale, methodology, and present status of the field. Inflamm Bowel Dis 2004; 10: 300-11.
14. Mannick, E.E., Zapata, A. Target genes for inflammatory bowel disease. US20070042364 (2007).
15. Belouchi, A., Raelson, J. V., Bradley, W. E., Paquin, B., Fournier, H., Nguyen-Huu, Q., Croteau, P., Allard, R., Briand, S., Van Eerdewegh, P., Little, R. D., Segal, J., Keith, T. Genemap of the human genes associated with crohn's disease. US20090181380 (2009).
16. Girardin SE, Boneca IG, Viala J, Chamaillard M, Labigne A, Thomas G, et al. NOD2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem 2003; 278: 8869-72.
17. Inohara N, Ogura Y, Fontalba A, Gutierrez O, Pons F, Crespo J, et al. Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease. J Biol Chem 2003; 278: 5509-512.
18. Ogura Y, Inohara N, Benito A, Chen FF, Yamaoka S, Nunez G, et al. Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-kappaB. J Biol Chem 2001; 276: 4812-8.
19. O'Neill LA. How NOD-ing off leads to Crohn disease. Nat Immunol 2004; 5: 776-8.
20. Abbott DW, Wilkins A, Asara JM, Cantley LC. The Crohn's disease protein, NOD2, requires RIP2 in order to induce ubiquitinylation of a novel site on NEMO. Curr Biol 2004; 14: 2217-7.
21. Inohara N, Koseki T, Lin J, del Peso L, Lucas PC, Chen FF, et al. An induced proximity model for NF-αB activation in theNod1/RICK and RIP signaling pathways. J Biol Chem 2000; 275: 27823-31.
22. Dave SH, Tilstra JS, Matsuoka K, Fengling L, Karrasch T, Uno JK, et al. Amelioration of chronic murine colitis by peptide-mediated transduction of the IαB kinase inhibitor NEMO-binding-domain peptide. J Immunol 2007; 179: 7852-9.
23. Shibata W, Maeda S, Hikiba Y, Ayako Y, Tomoya O, Kei S, et al. Cutting edge: The IαB kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks inflammatory injury in murine colitis. J Immunol 2007; 179: 2681-5.
24. Stronati L, Negroni A, Merola P, Pannone V, Borrelli O, Cirulli M, et al. Mucosal NOD2 expression and NF-αB activation in pediatric Crohn's disease. Inflamm Bowel Dis 2008; 14: 295-302.
25. Jae YK, Omori E. TAK1 is a central mediator of NOD2 signaling in epidermal cells. J Biol Chem 2008; 283(1): 137-44.
26. Hugot JP. CARD15/NOD2 mutations in Crohn's disease. Ann N Y Acad Sci 2006; 1072: 9-18.
27. Kobayashi KS, Chamaillard M, Ogura Y, Henegariu O, Inohara N, Nuñez G, et al. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 2005; 307: 731-4.
28. Shim JH, Xiao C, Paschal AE, Bailey ST, Rao P, Hayden MS, et al. TAK1, but not TAB1 or TAB2, plays an essential role in multiple signaling pathways in vivo. Genes Dev 2005; 19: 2668-81.
29. Dotan, N., Dukler, A., Altstock, R.T. Method for diagnosing and prognosing inflammatory bowel disease and crohn's disease. US20060205022 (2006).
30. Hershberg, R. M., Hosken, N. A., Lodes, M. J., Mohamath, R., Targan, S. R. Compositions and methods for the therapy and diagnosis of inflammatory bowel disease. US20090142778 (2009).
31. Nunez, G., Inohara, N., Ogura, Y. Modulators of NOD2 signalling. US20080280367 (2008).
32. Murphy CA, Langrish CL, Chen Y, Blumenschein W, McClanahan T, Kastelein RA, et al. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 2003; 198: 1951-7.
33. Hue S, Ahern P, Buonocore S, Kullberg MC, Cua DJ, McKenzie BS, et al. Interleukin-23 drives innate and T cell mediated intestinal inflammation. J Exp Med 2006; 203: 2473-83.
34. Fujino S, Andoh A, Bamba S, Ogawa A, Hata K, Araki Y, et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 2003; 52: 65-70.
35. Wolk K, Witte E, Hoffmann U, Doecke WD, Endesfelder S, Asadullah K, et al. IL-22 induces lipopolysaccharide-binding protein in hepatocytes: A potential systemic role of IL-22 in Crohn's disease. J Immunol 2007; 178: 5973-81.
36. Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006; 314: 1461-3.
37. Mannon PJ, Fuss IJ, Mayer L, Elson CO, Sandborn WJ, Present D, et al. Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med 2004; 351: 2069-79.
38. Giles-Komar, J., Heavner, G., Knight, D., Luo, J., Peritt, D., Scallon, B., Shealy, D. Anti-IL-12 antibodies, epitopes, compositions, methods and uses. US20090202549 (2009).
39. Dal Monte, P., Giles-Komar, J., Heavner, G., Knight, D., Khossravi, M., Luo, J., Shealy, D., Volkin, D. Anti-IL-12/23p40 antibodies, epitopes, formulations, compositions, methods and uses. US20090181027 (2009).
40. Klein, P. J., Klaus, S. J.,Kumar, A. M., Gong, B. Therapeutic compounds for inhibiting interleukin-12 signaling and methods for using same. US20050049262 (2005).
41. Mettens, P., Uyttenhove, C., Van Snick, J. Vaccine comprising IL- 12 or IL-23 for treatment of autoimmune diseases. US20070048261 (2007).
42. Diener, J. L., Ferguson, A., Hamaguchi, N., Keene, S. C., Lagasse, D. H. A., Sawhney, P., Thompson, K. Aptamers to the human IL- 12 cytokine family and their use as autoimmune disease therapeutics. US20070066550 (2007).
43. Lewis, K. E., Presnell, S.R., West, J. W., Mabry, R., Meengs, B., Levin, S. D. IL-17 and IL-23 antagonists and methods of using the same. US20080095775 (2008).
44. Dariavach P, Mattei MG, Golstein P, Golstein P, Lefranc MP, et al. Human Ig superfamily CTLA-4 gene: chromosomal localization and identity of protein sequence between murine and human CTLA-4 cytoplasmic domains. Eur J Immunol 1988; 18: 1901-5.
45. Harper K, Balzano C, Rouvier E, Mattéi MG, Luciani MF, Golstein P, et al. CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal location. J Immunol 1991; 147: 1037-44.
46. Luo Y, Xia B, Li C, Chen Z, Ge L, Jiang T, et al. Cytotoxic T lymphocyte antigen-4 promoter-658CT gene polymorphism is associated with ulcerative colitis in Chinese patients. Int J Colorectal Dis 2009; 24: 489-93.
47. Blumenthal RL, Campbell DE, Hwang P, DeKruyff RH, Frankel LR. Human alveolar macrophages induce functional inactivation in antigen-specific CD4 T cells. J Allergy Clin Immunol 2001; 107: 258-64.
48. Ariyan C, Salvalaggio P, Fecteau S, Deng S, Rogozinski L, Mandelbrot D, et al. Cutting edge: Transplantation tolerance through enhanced CTLA-4 expression. J Immunol 2003; 171: 5673-7.
49. Wu Y, Guo Y, Huang A, Huang A, Zheng P, Liu Y, et al. CTLA-4- B7 interaction is sufficient to costimulate T cell clonal expansion. J Exp Med 1997; 185: 1327-35.
50. Thompson CB, Allison JP. The emerging role of CTLA-4 as an immune attenuator. Immunity 1997; 7: 445-50.
51. Shwab M, Schaeffeler E, Marx C, Fromm MF, Kaskas B, Metzler J, et al. Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gastroenterology 2003; 124: 26-33.
52. Kristiansen OP, Larsen ZM, Pociot F. CTLA-4 in autoimmune diseases-a general susceptibility gene to autoimmunity. Genes Immun 2000; 1: 170-84.
53. Ueda H, Howson JM, Esposito L, Heward J, Snook H, Chamberlain G, et al. Association of the T-cell regulatory gene CTLA-4 with susceptibility to autoimmune disease. Nature 2003; 423: 506-11.
54. Abreu MT. The pathogenesis of inflammatory bowel disease: Translational implications for clinicians. Curr Gastroenterol Rep 2002; 4: 481-9.
55. Peltekova VD, Wintle RF, Rubin LA, Amos CI, Huang Q, Xiangjun G, et al. Functional variants of OCTN cation ransporter genes are associated with Crohn disease. Nat Genet 2004; 36: 471-5.
56. Cucchiara S, Latiano A, Palmieri O, Staiano AM, D'Incà R, Guariso G, et al. Role of CARD15, DLG5 and OCTN genes polymorphisms in children with inflammatory bowel diseases. World J Gastroenterol 2007; 13(8): 1221-9.
57. Noble CL, Nimmo ER, Drummond H, Ho GT, Tenesa A, Smith L, et al. The contribution of OCTN1/2 variants within the IBD5 locus to disease susceptibility and severity in Crohn's disease. Gastroenterology 2005; 129: 1854-64.
58. Peltekova, V. D., Wintle, R. F., Rubin, L. A., George-Hyslop, S. P.H., Siminovitch, K. A. Polymorphisms of the OCTN1 and OCTN2 cation transporters associated with inflammatory bowel disorders. US20040197777 (2004).
59. Levine B, Deretic V. Unveiling the roles of autophagy in innate and adaptive immunity. Nat Rev Immunol 2007; 7: 767-77.
60. Hampe J, Franke A, Rosenstiel P, Till A, Teuber M, Huse K, et al. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn diseasein ATG16L1. Nat Genet 2007; 39: 207-11.
61. Chen Z, Gibson TB, Robinson F, Silvestro L, Pearson G, Xu B, et al. MAP kinases. Chem Rev 2001; 101: 2449-76.
62. Broom OJ, Widjaya B, Troelsen J, Olsen J, Nielsen OH. Mitogen activated protein kinases: A role in inflammatory bowel disease? Clin Exp Immunol 2009; 158(3): 272-80.
63. Lee J, Mira-Arbibe L, Ulevitch RJ. TAK1 regulates multiple protein kinase cascades activated by bacterial lipopolysaccharide. J Leukoc Biol 2000; 68: 909-15.
64. Matsuzawa A, Saegusa K, Noguchi T, Sadamitsu C, Nishitoh H, Nagai S, et al. ROS-dependent activation of the TRAF6-ASK1-p38 pathway is selectively required for TLR4-mediated innate immunity. Nat Immunol 2005; 6: 587-92.
65. Hegen M, Gaestel M, Nickerson-Nutter CL, Lin LL, Telliez JB. MAPKAP kinase 2-deficient mice are resistant to collagen-induced arthritis. J Immunol 2006; 177(3): 1913-7.
66. Hollenbach E, Vieth M, Roessner A, Neumann M, Malfertheiner P, Naumann M. Inhibition of RICK/nuclear factor-kappaB and p38 signaling attenuates the inflammatory response in a murine model of Crohn disease. J Biol Chem 2005; 280: 14981-8.
67. Hollenbach E, Neumann M, Vieth M, Roessner A, Malfertheiner P, Naumann M. Inhibition of p38 MAP kinase- and RICK/NFkappaB- signaling suppresses inflammatory bowel disease. FASEB J 2004; 18: 1550-2.
68. Atreya I, Atreya R, Neurath MF. NF-kappaB in inflammatory bowel disease. J Intern Med 2008; 263: 591-6.
69. Yoh I, Tatsuya O, Hirotake S. Macrophage migration inhibitory factor has a proinflammatory activity via the p38 pathway in glucocorticoid-resistant ulcerative colitis. Clin Immunol 2006; 120: 335-41.
70. Bozena K. MAPK signalling pathways as molecular targets for anti-inflammatory therapy- from molecular mechanisms to therapeutic benefits. Biochim Biophys Acta 2005; 1754: 253-62.
71. Mavunkel, B. J., Perumattam, J. J., Lu, Q., Dugar, S., Goyal, B., Wang, X. D., Chakravarty, S., Luedtke, G. R., Nashashibi, I., Tester, R., Tan, X. Azaindole derivatives as inhibitors of p38 kinase. US20050288299 (2005).
72. Severance, D. L., Gardiner, E. M. M., Noble, S.A., Lou, B., Borchardt, A.J., Roppe, J.R., Kahraman, M., Siegel, D. L., Scranton, S. A. Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders. US20060252807 (2006).
73. Dong, Q., Wang, J., Lang, H., Lan, J. Bicyclic heterocyclic p-38 kinase inhibitors. US20070142405 (2007).
74. Bemis, G. W., Salituro, F. G., Duffy, J. P., Cochran, J. E., Harrington, E. M., Murcko, M.A.,Wilson, K.P., Su, M., Galullo, V. P. Inhibitors of p38. US20090203702 (2009).
75. Moffat, D. C. F., Pintat, S., Davies, S. P38 map kinase inhibitors. US20090099185 (2009).
76. Nagle, A., Gray, N. S., Liu, Y., Ren, P., Sim, T., You, S. Inhibitors of protein kinases. US20090118273 (2009).
77. Michelotti, E.L., Moore, W.R. Jr., Springman, E.B. Inhibitors of protein kinases. US20070185098 (2007).
78. Roy PK, Rashid F, Bragg J, Ibdah JA. Role of the JNK signal transduction pathway in inflammatory bowel disease. World J Gastroenterol 2008; 14: 200-202.
79. Jeong HS, Choi HY, Choi TW, Kim B-W, Kim J-H, Lee E-R, et al. Differential regulation of the antiapoptotic action of B-cell lymphoma 2 (Bcl-2) and B-cell lymphoma extra long (Bcl-xL) by c-Jun N-terminal protein kinase (JNK) 1-involved pathway in neuroglioma cells. Biol Pharm Bull 2008; 31: 1686-90.
80. Aud D, Peng SL. Mechanisms of disease: transcription factors in inflammatory arthritis. Nat Clin Pract Rheumatol 2006; 2: 434-42.
81. Turkson J, Bowman T, Adnane J, Zhang Y, Djeu JY, Sekharam M, et al. Requirement for Ras/Rac1-mediated p38 and c-Jun Nterminal kinase signaling in Stat3 transcriptional activity induced by the Src oncoprotein. Mol Cell Biol 1999; 19: 7519-28.
82. Atreya R, Mudter J, Finotto S, Müllberg J, Jostock T, Wirtz S, et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo. Nat Med 2000; 6: 583-8.
83. Peterson RL, Wang L, Albert L, Keith JC Jr, Dorner AJ. Molecular effects of recombinant human interleukin-11 in the HLA-B27 rat model of inflammatory bowel disease. Lab Invest 1998; 78: 1503-12.
84. Cohen PS, Nakshatri H, Dennis J, Caragine T, Bianchi M, Cerami A, et al. CNI-1493 inhibits monocyte/macrophage tumor necrosis factor by suppression of translation efficiency. Proc Natl Acad Sci USA 1996; 93: 3967-71.
85. Hommes D, van den Blink B, Plasse T, Bartelsman J, Xu C, Macpherson B, et al. Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. Gastroenterology 2002; 122: 7-14.
86. Halazy, S., Church, D., Camps, M. Method of inhibiting the expression and/or the activity of JNK. US20070259892 (2007).
87. Bhagwat, S.S., Satoh, Y., Sakata, S.T. Methods for treating an inflammatory condition or inhibiting JNK. US20040127536 (2004).
88. Itoh, F., Kimura, H., Igata, H. JNK inhibitor. US20050148624 (2005).
89. Graczyk, P., Khan, A., Bhatia, G., Iimura, Y. JNK inhibitors. US20090215771 (2009).
90. Kyriakis JM, Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 2001; 81(2): 807-69.
91. Jonas M, Markus FN. The role of signal transducers and activators of transcription in t inflammatory bowel diseases. Inflamm Bowel Dis 2003; 9(5): 332-7.
92. Shimoda K, Kato K, Aoki K, Matsuda T, Miyamoto A, Shibamori M, et al. Tyk2 plays a restricted role in IFN alpha signaling, although it is required for IL-12-mediated T cell function. Immunity 2000; 13: 561-71.
93. Candotti F, Notarangelo L, Visconti R, O'Shea J. Molecular aspects of primary immunodeficiencies: Lessons from cytokine and other signaling pathways. J Clin Invest 2002; 109: 1261-9.
94. Akira A, Makoto S, Atsushi N, Bamba S, Tsujikawa T, Kim- Mitsuyama S, et al. Expression of IL-24, an activator of the JAK1/ STAT3/SOCS3 cascade, is enhanced in inflammatory bowel disease. J Immunol 2009; 183: 687-95.
95. Li, H., Thota, S., Carroll, D., Argade, A., Tso, K., Sran, A., Clough, J., Keim, H., Bhamidipati, S., Taylor, V., Cooper, R., Singh, R., Wong, B. Compositions and methods for inhibition of the JAK pathway. US20090041786 (2009).
96. Burns, C.J., Wilks, A.F. Methods of inhibiting kinases. US20060069084 (2006).
97. Salituro, F., Farmer, L., Bethiel, R., Harrington, E., Green, J., Court, J., Come, J., Lauffer, D., Aronov, A., Binch, H., Boyall, D., Charrier, Jean-D., Everitt, S., Fraysse, D., Mortimore, M., Pierard, F., Robinson, D., Wang, J., Pinder, J., Wang, T., Pierce, A. Azaindoles useful as inhibitors of JAK and other protein kinases. US20090176763 (2009).
98. Ledeboer, M., Ledford, B. Compositions useful as inhibitors of JAK and other protein kinases. US20040147507 (2004).
99. Strober, W., Fuss, I., Neurath, M., Kitani, A. Methods of treating colitis using STAT-4 anti-sense oligonucleotides. US20020077308 (2002).
100. Huang, A., Liu, J., Medina, J., Wang, X., Xu, F., Zhu, L. STAT modulators. US20050101540 (2005).
101. Kruidenier L, Kuiper I, Lamers CB, Verspaget HW. Intestinal oxidative damage in inflammatory bowel disease: Semiquantification, localization, and association with mucosal antioxidants. J Pathol 2003; 201: 28-36.
102. Yukawa M, Iizuka M, Horie Y, Yoneyama K, Shirasaka T, Itou H, et al. Systemic and local evidence of increased Fas-mediated apoptosis in ulcerative colitis. Int J Colorectal Dis 2002; 17: 70-6.
103. Hagiwara C, Tanaka M, Kudo H. Increase in colorectal epithelial apoptotic cells in patients with ulcerative colitis ultimately requiring surgery. J Gastroenterol Hepatol 2002; 17(7): 758-64.
104. Strater J, Moller P. Expression and function of death receptors and their natural ligands in the intestine. Ann NY Acad Sci 2000; 915: 162-70.
105. Barnhart BC, Pietras EM, Geciras-Schimnich A, Barnhart BC, Pietras EM, Algeciras-Schimnich A, et al. CD95 apoptosis resistance in certain cells can be overcome by noncanonical activation of caspase-8. Cell Death Differ 2005; 12: 25-37.
106. Susin SA, Daugas E, Ravagnan L, Samejima K, Zamzami N, Loeffler M, et al. Two distinct pathways leading to nuclear apoptosis. J Exp Med 2000; 192: 571-80.
107. Roy S, Nicholson DW. Cross-talk in cell death signaling. J Exp Med 2000; 192: F21-5.
108. Al-Mashat HA, Kandru S, Liu R, Behl Y, Desta T, Graves DT. Diabetes enhances mRNA levels of proapoptotic genes and caspase activity, which contribute to impaired healing. Diabetes 2006; 55(2): 487-95.
109. Lee P, Lee DJ, Chan C, Chen S-W, Ch'en I, Jamora C. Dynamic expression of epidermal caspase 8 simulates a wound healing response. Nature 2009; 458(7237): 519-23.
110. Ueyama H, Kiyohara T, Sawada N, Isozaki K, Kitamura S, Kondo S, et al. High Fas ligand expression on lymphocytes in lesions of ulcerative colitis. Gut 1998; 43: 48-55.
111. Hawkins PT. Signalling through class I PI3Ks in mammalian cells. Biochem Soc Trans 2006; 34: 647-62.
112. Lindemans CA, Coffer PJ. Regulation of granulocyte apoptosis by phosphatidylinositol 3-kinase. Biochem Soc Trans 2004; 32: 480-4.
113. Yang KY, Arcaroli J, Kupfner J, Pitts MT, Park JS, Strasshiem D, et al. Involvement of phosphatidylinositol 3-kinase γ in neutrophil apoptosis. Cell Signal 2003; 15: 225-33.
114. Cowburn AS, Deighton J, Walmsley SR, Chilvers ER. The survival effect of TNF-α in human neutrophils is mediated via NF-kBdependent IL-8 release. Eur J Immunol 2004; 34: 1733-43.
115. Bruewer M, Utech M, Ivanov AI, Hopkins AM, Parkos CA, Nusrat A. Interferon-gamma induces internalization of epithelial tight junction proteins via a macropinocytosis-like process. FASEB J 2005; 19: 923-33.
116. Boivin MA, Roy PK, Bradley A, Kennedy JC, Rihani T, Ma TY, et al. Mechanism of interferon-γ-induced increase in T84 intestinal epithelial tight junction. J Interferon Cytokine Res 2009; 29(1): 45-54.
117. Shirasaka T, Iizuka M, Yukawa M, Hirai Y, Horie Y, Itou H, et al. Altered expression of epimorphin in ulcerative colitis. J Gastroenterol Hepatol 2003; 18: 570-7.
118. Masahiro I, Kenji S, Yohei H, Shindo K, Konno S, Itou H, et al. Morphogenic protein epimorphin protects intestinal epithelial cells from oxidative stress by the activation of EGF receptor and MEK/ERK, PI3 kinase/Akt signals. Am J Physiol Gastrointest Liver Physiol 2007; 292: G39-G52.
119. Koyasu, S., Ohtani, M., Sasakaw, C., Yoshida, S. Inhibitor of PI3 kinase-dependent inflammatory cytokine synthesis and method for inhibiting the same. US20080317875 (2008).
120. Adams, N. D., Burgess, J. L., Darcy, M. G., Donatelli, C. A., Knight, S.D., Newlander, K. A., Ridgers, L., Sarpong, M. A., Schmidt, S. J. Quinoline derivatives as PI3 kinase inhibitors. US20080300239 (2008).
121. Adams, N. D., Dhanak, D., Knight, S. D., Schaller, L., Tang, J. Thiozolidinedione derivatives as PI3 kinase inhibitors. US20090215818 (2009).
122. Didierlaurent A, Sirard JC, Kraehenbuhl JP, Neutra MR. How the gut senses its content. Cell Microbiol 2002; 4: 61-72.
123. Takeda K, Akira S. TLR signaling pathway. Semin Immunol 2004; 16: 3-9.
124. Adam GT, Kumar V. Toll-like receptors and their role in gastrointestinal disease. J Gastroenterol Hepatol 2009; 24: 943-954.
125. Daniel CB. Immunopathogenesis of infammatory bowel disease. World J Gastroenterol 2008; 14(3): 390-400.
126. Maynard CL, Weaver CT. Intestinal effector T cells in health and disease. Immunity 2009; 31(3): 389-400.
127. Xu T, Ling-Fen X, Ping Z, Sun HW, Sun M. Effects of trefoil peptide 3 on expression of TNF-α, TLR4, and NF-kB in trinitrobenzene sulphonic acid induced colitis mice. Inflammation 2009; 32(2): 120-9.
128. Torok HP, Glas J, Tonenchi L, Mussack T, Glas J, Tonenchi L, et al. Polymorphisms of the lipopolysaccharide-signaling complex in inflammatory bowel disease: Association of a mutation in the Toll-like receptor 4 gene with ulcerative colitis. Clin Immunol 2004; 112: 85-91.
129. Franchimont D, Vermeire S, El Housni H, Pierik M, Van Steen K, Gustot T, et al. Deficient host-bacteria interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn's disease and ulcerative colitis. Gut 2004; 53: 987-92.
130. De Jager PL, Franchimont D, Waliszewska A, Bitton A, Cohen A, Langelier D, et al. The role of the Toll receptor pathway in susceptibility to inflammatory bowel diseases. Genes Immun 2007; 8: 387-97.
131. Upadhyay, S., Kanekar, Y., Kshirsagar, R., Rajagopal, V., Datla, P., Bellary, A., Singh, S. P. Toll like receptor (TLR) signaling antagonist. US20090215908 (2009).
132. Upadhyay, S., Sharma, A., Sharma, A., Rajagopal, V., Datla, P., Bellary, A., Singh, Shiva P. Carbohydrate based toll-like receptor (tlr) antagonists. US20090215710 (2009).
133. Chow, J., Gusovksy, F., Hawkins, L., Spyvee, M. Compounds and methods for treating toll-like receptor 2-related diseases and conditions. US20070167409 (2007).
134. Kandimalla, E., Wang, D., Li, Y., Yu, D., Zhu, F., Bhagat, L., Agrawal, S. Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response US20090087388 (2009).
135. Kohn, L. D., Harii, N., Benavides-Peralta, U., Gonzalez- Murguiondo, M., Lewis, C. J., Napolitano, G., Giuliani, C., Malgor, R., Goetz, D. J. Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression. US20060211752 (2006).
136. Soderholm JD, Olaison G, Peterson KH, Franzén LE, Lindmark T, Wirén M, et al. Augmented increase in tight junction permeability by luminal stimuli in the non-inflamed ileum of Crohn's disease. Gut 2002; 50: 307-13.
137. Veldhoen M, Hocking RJ, Atkins CJ, Locksley R M, Stockinger B. TGF-β in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006; 24: 179-89.
138. Hart AL, Al-Hassi HO, Rigby RJ, Bell SJ, Emmanuel AV, Knight SC, et al. Characteristics of intestinal dendritic cells in inflammatory bowel diseases. Gastroenterology 2005; 129: 50-65.
139. Steinman RM, Nussenzweig MC. Avoiding horror autotoxicus: The importance of dendritic cells in peripheral T cell tolerance. Proc Natl Acad Sci USA 2002; 99: 351-8.
140. Manuel AS, Jennifer J. Intestinal epithelial barrier dysfunction and dendritic cell redistribution during early stages of inflammation in the rat: Role for TLR-2 and -4 blockage. Inflamm Bowel Dis 2008; 14: 632-44.
141. Hokama A, Mizoguchi E, Sugimoto K, Shimomura Y, Tanaka Y, Yoshida M, et al. Induced reactivity of intestinal CD4 (+) T cells with an epithelial cell lectin, galectin-4, contributes to exacerbation of intestinal inflammation. Immunity 2004; 20: 681-93.
142. Park H, Li Z, Yang XO, Chang SH, Chang SH, Nurieva R, et al. A distinct lineage of CD4+T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005; 6: 1133-41.
143. Lawless, O. Treatment of inflammatory, non-infectious, autoimmune, vasculitic, degenerative vascular, host-v-graft diseases, Alzheimers disease, and amyloidosis using mammalian, dsDNA vaccination. US20060111316 (2006).
144. Delucia, D. Adjuvant combinations comprising a microbial tlr agonist, a cd40 or 4-1bb agonist, and optionally an antigen and the use thereof for inducing a synergistic enhancement in cellular immunity. US20080241139 (2008).
145. Pizarro TT, Cominelli F. Cytokine therapy for Crohn's disease: advances in translational research. Annu Rev Med 2007; 58: 433-4.
146. Elson CO, Cong Y, Weaver CT, Schoeb TR, McClanahan TK, Fick RB, et al. Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice. Gastroenterology 2007; 132: 2359-70.
147. Chen FE, Ghosh G. Regulation of DNA binding by Rel/NF-kB transcription factors: Structural views. Oncogene 1999; 18: 6845-52.
148. Birbach A, Gold P, Binder BR Hofer E, de Martin R, Schmid JA. Signaling molecules of the NF-kappa B pathway shuttle constitutively between cytoplasm and nucleus. J Biol Chem 2002; 277: 10842-51.
149. Spehlmann ME, Eckmann L. Nuclear factor-kappa B in intestinal protection and destruction. Curr Opin Gastroenterol 2009; 25: 92-9.
150. Elke C, Daniel KP. Toll-Like Receptor signaling and its relevance to intestinal inflammation. Ann NY Acad Sci 2006; 1072: 332-8.
151. Uwe S. Anti-inflammatory interventions of NF-kappaB signaling: Potential applications and risks. Biochem Pharmacol 2008; 75(8): 1567-79.
152. Sinn DI, Lee ST, Chu K, Jung K-H, Kim E-H, Kim J-M, et al. Proteasomal inhibition in intracerebral hemorrhage: Neuroprotective and anti-inflammatory effects of bortezomib. Neurosci Res 2007; 58 (1): 12-8.
153. Dev, I.K., Subbiah, V. Triterpene derivatives for the treatment of cancer and inflammatory disease by inhibition of NF-KappaB. US20090036524 (2009).
154. Tepe, J.J. NF-kappaB inhibitors and uses thereof. US20050020586 (2005).
155. Callahan, J.F., Roshak, A.K. NF-kappaB inhibitors. US20060030596 (2006).
156. Beyaert, R., Heyninck, K., Fiers, W. Novel inhibitors of NFkappaB activation. US20040092430 (2004).
157. Callahan, J.F., Chabot-fletcher, M.C. Inhibitors of transcription factor NF-kappaB. US20060035979 (2006).
158. Strober, W., Fuss, I., Kitani, A., Fichtner-Feighl, S. Compositions and methods for the treatment of inflammatory bowel disease utilizing NF-KappaB decoy polynucleotides. US20090214630 (2009).